PT Kalbe Farma Tbk 2018 AR2
The report highlights PT Kalbe Farma Tbk's performance in 2018, during which the company achieved net sales of IDR 21,074 billion, representing a 4.4% growth compared to the previous year. Key achievements include the official inauguration of Kalbio Global Medika, a biologics manufacturing facility for biosimilar products, by the President of Indonesia. The company also expanded its international presence by entering the Chinese market and established strategic partnerships with Westland Milk and Fonterra Dairy. Additionally, Kalbe prepared its Group Sustainability Policy and continued its commitment to community development, investing IDR 92 billion in corporate social responsibility activities.
Company: PT Kalbe Farma Tbk
Sector: Health Care
Country: Indonesia
Year: 2018
Type: AR2
Pages: 444
Back to company
PT Kalbe Farma Tbk
Annual Report
The report highlights PT Kalbe Farma Tbk's performance in 2018, during which the company achieved net sales of IDR 21,074 billion, representing a 4.4% growth compared to the previous year. Key achievements include the official inauguration of Kalbio Global Medika, a biologics manufacturing facility for biosimilar products, by the President of Indonesia. The company also expanded its international presence by entering the Chinese market and established strategic partnerships with Westland Milk and Fonterra Dairy. Additionally, Kalbe prepared its Group Sustainability Policy and continued its commitment to community development, investing IDR 92 billion in corporate social responsibility activities.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2018
Reporting Period
Jan 1, 2018 - Dec 31, 2018
Fiscal Year
2018
Type
Annual Report with Sustainability Disclosures
Language
English, Indonesian
Pages
File Size
Standards & Assurance
Reporting Standards
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Employees